Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. (UNCY)

Core Viewpoint - A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly making false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application for oxylanthanum carbonate [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025 [1]. - The complaint alleges that the company overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its New Drug Application [2]. Group 2: Stock Price Impact - Following the announcement of deficiencies identified by the FDA in the company's manufacturing compliance, Unicycive's stock price fell by $3.68 per share, representing a 40.89% decline, closing at $5.32 per share on June 10, 2025 [3]. Group 3: Investor Information - Investors who acquired shares of Unicycive are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on October 14, 2025 [4].